Register to receive a free European Market Report Suite for Vascular Access Devices and Accessories 2017 report synopsis and brochure

According to a new series of reports on the European markets for vascular access devices by iData Research, the syringe and needle segment is experiencing different growth trends. The majority of syringes and needles in Europe are sold separately and combined when used, but there are some unique markets such as Italy where high sales of syringes and needles already attached, make the standalone market small by comparison. Products in this market are perceived as commodities and, as a result, the increase in average selling price (ASP) is limited by pricing pressure. The declines in ASP will be more substantial for safety devices with the declines in ASP for safety needles nearly double the declines for conventional needles.

The implementation of the directive by the Council of the European Union which aims to reduce needlestick injuries in hospitals has led the healthcare sector to a significant conversion from conventional to safety needles. In addition to the conversion to premium-priced safety needles, the use of two needles instead of one is leading to an increase in unit sales. While one needle is used to aspirate the medication into the syringe the other is used for injection.

“Total syringe unit sales are increasing at a slower pace than total needle sales, due in part to the declining unit sales of insulin syringes, which are incorporated into the overall syringe market,” explains Dr. Kamran Zamanian, CEO of iData. “The decrease in unit sales of insulin syringes is taking place due to the shift towards the use of insulin pen needles.”

The syringe market in Europe is a mature market with growth in unit sales dependent upon hospitalization rates. In contrast to the needle market, the syringe market is not benefiting as significantly from a shift towards the use of safety syringes. When used in combination the emphasis is on using a safety needle and not necessarily a safety syringe. Nonetheless, the syringe market is experiencing a shift towards the use of more expensive three-part syringes which is leading to growth in the overall market value.

Becton Dickinson is the leading competitor in the European syringe and needle market. The company produces millions of syringes and takes advantage of economies of scale to produce and sell syringes at a lower cost than many of its competitors. This has caused the ASP of many segments of the total market for syringes and needles to decline as companies attempt to remain competitive. Becton Dickinson’s syringe and needle portfolio includes the SafetyGlide™ shielding hypodermic needle, the Safety-Lok™ sliding sheath syringe, the Eclipse™ pivoting blood collection needle and the Integra™ retractable syringe.

B. Braun is the second leading competitor in the European total syringe and needle market. The company has gained significant market share in the past several years, especially in regions such as Germany. B. Braun manufactures standard and fine dose two-part and three-part syringes as well as insulin and irrigation syringes for sale in Europe. Additional competitors in the European syringe and needle market include Terumo, Artsana, Pentaferte, Novico, Rays, Smiths Medical and SFM among others.

For Further Information
More on the syringe and needle device market in Europe can be found in a series of reports published by iData Research entitled the European Markets Report Suite for Vascular Access Devices and Accessories.